ENDRA Life Sciences (NDRA) Cash from Financing Activities (2016 - 2026)

ENDRA Life Sciences has disclosed Cash from Financing Activities across 11 years of filings, most recently posting $263747.0 for Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 80.89% year-over-year to $263747.0; the TTM figure through Mar 2026 stood at $5.9 million (down 21.84% YoY), while the FY2025 annual figure was $5.7 million, down 26.59% from the prior year.
• Cash from Financing Activities retreated to $263747.0 in Q1 2026, from $4.6 million in the prior quarter.
• Over the last five years, Cash from Financing Activities for NDRA reached as high as $7.5 million in Q2 2022 and fell as low as $1683.0 in Q3 2024.
• The 5-year median for Cash from Financing Activities is $857415.0 (2025), against an average of $2.3 million.
• Annual changes were most pronounced in 2024 — Cash from Financing Activities slumped 99.85% — and 2025, when it surged 8780.93%.
• A 5-year view of Cash from Financing Activities shows it stood at $7.5 million in 2022, then slumped by 77.85% to $1.7 million in 2023, then sank by 99.9% to $1683.0 in 2024, then jumped by 272035.41% to $4.6 million in 2025, then tumbled by 94.24% to $263747.0 in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $263747.0, $4.6 million, and $149466.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.